乙型肝炎肝硬化患者肠道菌群变化研究*

doi:10.3969/j.issn.1672-5069.2020.02.027

摘要/Abstract

摘要： 目的分析乙型肝炎肝硬化患者肠道菌群的分布情况及其临床意义。方法 2018年 7月～2019年4月我院收治的乙型肝炎肝硬化患者103例(代偿期肝硬化41例和失代偿期肝硬化62例)和同期健康人群20例,采集粪便,采用Illumina Miseq测序法分析肠道菌群结构差异和物种多样性。结果在健康人,巨单胞菌属、拟杆菌属和粪杆菌属分别为14.8%、11.4%和9.8%,在代偿期肝硬化组,拟杆菌属、粪杆菌属和巨单胞菌属比例分别为15.2%、11.5%和11.2%,在失代偿期肝硬化组,拟杆菌属、粪杆菌属和韦荣球菌属比例分别为16.9%、9.6%和9.2%;健康人Chao指数为(1250.5±283.7),显著高于代偿期肝硬化组【(1111.5±277.1),P＜0.05】或失代偿期肝硬化组【(910.2±369.6),P＜0.05】,健康人Shannon指数为(3.7±0.6),显著高于代偿期肝硬化组【(3.5±0.1),P＜0.05】或失代偿期肝硬化组【(3.3±0.4),P＜0.05】,健康人Simpson指数为(0.3±0.1),显著高于代偿期肝硬化组【(0.2±0.1),P＜0.05】或失代偿期肝硬化组【(0.1±0.4),P＜0.05】。结论乙型肝炎肝硬化患者肠道菌群丰度和多样性降低,失代偿期肝硬化患者肠道菌群变化更为明显,即存在随着病情进展肠道菌群多样性减少现象,其临床意义值得探讨。

关键词: 肝硬化, 肠道菌群, 物种丰度

Abstract: Objective The aim of this study was to analyze the distribution of intestinal flora in patients with hepatitis B liver cirrhosis. Methods A total of 103 patients with hepatitis B liver cirrhosis (compensated cirrhosis in 41 and decompensated cirrhosis in 62) and 20 healthy persons were enrolled in our hospital between July 2018 and April 2019, and the sequences of intestinal bacteria were carried out by Illumina Miseq. Results At the genius level, the proportion of Megamonas, Bacteroides and Faecalibacterium in the healthy persons were 14.8%, 11.4% and 9.8%, the proportion of Bacteroides, Faecalibacterium and Megamonas in patients with compensated cirrhosis were 15.2%, 11.5% and 11.2%, while the proportion of Bacteroides, Faecalibacterium and Veillonella in patients with decompensated liver cirrhosis were 16.9%, 9.6% and 9.2%, respectively; we used Chao, Shannon and Simpson index to analyze the flora abundance and diversity, and the Chao index in healthy persons was (1250.5 ±283.7), significantly higher than (1111.5±277.1,P＜0.05) in patients with compensated or (910.2 ±369.6, P＜0.05) in decompensated liver cirrhosis, the Shannon index in healthy persons was (3.7±0.6), significantly higher than (3.5 ±0.1,P＜0.05) in patients with compensated or (3.3±0.4,P＜0.05) in decompensated liver cirrhosis, and the Simpson index in the healthy persons was (0.3 ± 0.1), significantly higher than (0.2±0.1, P＜0.05) in patients with compensated or (0.1±0.4, P＜0.05) in patients with decompensated liver cirrhosis. Conclusion The intestinal flora abundance and diversity in patients with hepatitis B liver cirrhosis decrease as the progress of the disease, which might have a significant implications in dealing with the patients in clinical practice.

Key words: Liver cirrhosis, Intestinal flora, Species abundance

邢乐康, 邓永东, 姚立琼, 金凤玲. 乙型肝炎肝硬化患者肠道菌群变化研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 256-259.

Xing Lekang, Deng Yongdong, Yao Liqiong, et al. Changes of intestinal flora in patients with hepatitis B liver cirrhosis[J]. Journal of Practical Hepatology, 2020, 23(2): 256-259.

参考文献

[1] Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol,2015, 21(41): 11597-11608.
[2] Ohtani N , Kawada N. Role of the gut–liver axis in liver inflammation, fibrosis, and cancer:a special focus on the gut microbiota relationship. Hepatol Commun,2019,3(4):456-470.
[3] Johnson AJ, Vangay P, Al-Ghalith GA, et al. Daily sampling reveals personalized diet-microbiome associations in humans. Cell Host Microbe,2019,25(6):789-802.
[4] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):389-400.
[5] Milosevic I ,Vujovic A ,Barac A,et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci,2019,20(2):395-411.
[6] Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases.Gut,2016,10(65):2035-2044.
[7] Hatton G ,Shawcross DL. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis. Expert Rev Gastroenterol Hepatol,2019, 13(1):1-2.
[8] 王艺璇,李炜,程丹颖,等.乙型肝炎失代偿期肝硬化患者肠道菌群特征.中华实验和临床感染病杂志(电子版),2019,13(2):110-116.
[9] Betrapally NS, Gillevet PM, Bajaj JS,et al. Gut microbiome and liver disease. Transl Res,2017,1(179):49-59.
[10] Sanduzzi Zamparelli A, Rocco A,Compare D, et al. The gut microbiota: a new potential driving force in liver cirrhosis and hepatocellular carcinoma. Unit Eur Gastroenterol J,2017,5(7):944-953.
[11] Muniz Pedrogo DA, Jensen MD, Van Dyke CT,et al. Gut microbial carbohydrate metabolism hinders weight loss in overweight adults undergoing lifestyle intervention with a volumetric diet. Mayo Clin Proc,2018, 8(93):1104-1110.
[12] 赵煜桢,周少明.饮食对非酒精性脂肪性肝病患者肠道菌群的影响.国际消化病杂志,2018,38(6):361-364,373.
[13] Bajaj JS, Idilman R, Mabudian L ,et al. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology, 2018,68(1):234-247.
[14] 徐艳丽, 尹霞, 常英. 肠道菌群失衡在结直肠癌发病过程中的作用. 国际消化病杂志, 2014,34(2):124-127.
[15] Mashima I, Nakazawa F. The influence of oral veillonella species on biofilms formed by streptococcus species.Anaerobe,2014,28(1):54-61.
[16] Giannelli V,Di Gregorio V, Iebba V,et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol,2014 ,20(45):16795-16810.
[17] Zhang FM, Cui BT, He XX ,et al. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell,2018,9(5):462–473.
[18] Bajaj JS, Cox IJ, Betrapally NS, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gutmicrobiota composition and function. Am J Physiol Gastrointest Liver Physiol,2014,307(10):951-957.
[19] Bajaj JS, Betrapally NS, Hylemon PB, et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes. Mell Sci Rep,2015,22(5):18559-18567.
[20] Wang J, Wang Y, Zhang X,et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol,2017,8(13):2222-2234.
[21] Kang Y, Cai Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect,2017,96(4):342-348.

乙型肝炎肝硬化患者肠道菌群变化研究^*

Changes of intestinal flora in patients with hepatitis B liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张玉玲, 周瑾, 董宏伟. 超声点定量弹性成像技术对AIH和PBC患者肝纤维化诊断价值分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 231-235.
[2]	贾娇, 王芳, 张波, 武琼. 熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 240-243.
[3]	张惠勇, 吴秀欣, 徐成润. 特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 244-247.
[4]	阿思根, 夏医君, 武慧军, 薛荣泉, 辛瑞强, 白斯古楞, 赵德芳. 脾切除术联合门奇静脉断流术治疗肝硬化门脉高压症患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 248-251.
[5]	胡星, 孟繁坤, 韩晶, 张旭辉. 应用超声心动图评估肝硬化患者心脏结构和功能临床价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 252-255.
[6]	徐小元. 解读肝硬化诊治指南难点与新颖之处[J]. 实用肝脏病杂志, 2020, 23(1): 4-6.
[7]	杨晓玲, 张素梅. SGA、MNA和NRS2002评估失代偿期肝硬化患者营养状态应用价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 70-73.
[8]	王晶晶, 李春涛, 周卫真. 失代偿期乙型肝炎肝硬化患者尿液视黄醇结合蛋白水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 74-77.
[9]	杨慧玲, 刘小静, 何英利, 杜粉静, 叶峰. 失代偿期乙型肝炎肝硬化患者发生医院感染临床特点及危险因素分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 78-81.
[10]	赵平, 黎涛, 谢吉良, 郑波. 早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 82-85.
[11]	张冰, 解学军. 酒精性肝硬化患者血CTLA-4和PNPLA3基因多态性及其临床意义分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 86-89.
[12]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[13]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[14]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[15]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.